{
    "name": "copper CU 64 dotatate",
    "comment": "Rx",
    "other_names": [
        "Detectnet"
    ],
    "classes": [
        "Diagnostic Imaging Agents"
    ],
    "source": "https://reference.medscape.com/drug/detectnet-copper-cu-64-dotatate-4000125",
    "pregnancy": {
        "common": [
            "There are no studies in pregnant females to inform any drug-associated risks; however, all radiopharmaceuticals have the potential to cause fetal harm",
            "Assess pregnancy status in females of reproductive potential before administering"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "There is no information on the presence of copper CU 64 dotatate in human milk, the effect on the breastfed infant, or the effect on milk production",
            "Advise breastfeeding females to interrupt breastfeeding and pump and discard breast milk for 12 hr after administration to minimize radiation exposure to a breastfed infant"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Hypersensitivity reactions consisting of cutaneous reactions such as rash and pruritus reported; reactions reversed either spontaneously or with routine symptomatic management; less frequently hypersensitivity reactions included angioedema or cases with features of anaphylaxis"
            ],
            "specific": [
                {
                    "type": "Radiation risk",
                    "description": [
                        "Contributes to a patientâ€™s overall long-term cumulative radiation exposure; long-term cumulative radiation exposure associated with increased cancer risk",
                        "Ensure safe handling and preparation procedures to protect patients and healthcare workers from unintentional radiation exposure"
                    ]
                },
                {
                    "type": "Risk for image misinterpretation",
                    "description": [
                        "Uptake of copper CU 64 dotatate reflects somatostatin receptor density in NETs",
                        "Uptake can also be seen in a variety of other tumor types that express somatostatin receptors (eg, thyroid disease) or in subacute inflammation, or a normal physiologic variant (eg, uncinate process of the pancreas)",
                        "Uptake may need to be confirmed by histopathology or other assessments to confirm NET diagnosis"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Nonradioactive somatostatin analogs competitively bind to the same somatostatin receptors as copper CU 64 dotatate",
                        "Long-acting somatostatin analogs: 28-day washout period recommended before imaging",
                        "Short-acting somatostatin analogs: 2-day washout period recommended before imaging"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lanreotide",
            "description": {
                "common": "lanreotide decreases effects of copper CU 64 dotatate by receptor binding competition. Modify Therapy/Monitor Closely. Somatostatin analogs competitively bind to the same somatostatin receptors as CU 64 dotatate and may affect imaging. Image patients just prior to dosing with somatostatin analogs. Washout period of 28 days recommended for patients on long-acting somatostatin analogs before imaging; whereas, 2 days washout recommended for short-acting somatostatin analogs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "octreotide",
            "description": {
                "common": "octreotide decreases effects of copper CU 64 dotatate by receptor binding competition. Modify Therapy/Monitor Closely. Somatostatin analogs competitively bind to the same somatostatin receptors as CU 64 dotatate and may affect imaging. Image patients just prior to dosing with somatostatin analogs. Washout period of 28 days recommended for patients on long-acting somatostatin analogs before imaging; whereas, 2 days washout recommended for short-acting somatostatin analogs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pasireotide",
            "description": {
                "common": "pasireotide decreases effects of copper CU 64 dotatate by receptor binding competition. Modify Therapy/Monitor Closely. Somatostatin analogs competitively bind to the same somatostatin receptors as CU 64 dotatate and may affect imaging. Image patients just prior to dosing with somatostatin analogs. Washout period of 28 days recommended for patients on long-acting somatostatin analogs before imaging; whereas, 2 days washout recommended for short-acting somatostatin analogs."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Nausea",
            "percent": "2"
        },
        {
            "name": "Vomiting",
            "percent": "2"
        },
        {
            "name": "Flushing",
            "percent": "2"
        },
        {
            "name": "Immune system disorders",
            "percent": null
        },
        {
            "name": "Hypersensitivity reactions",
            "percent": null
        },
        {
            "name": "predominantly rash",
            "percent": null
        },
        {
            "name": "pruritus",
            "percent": null
        },
        {
            "name": "less frequently angioedema or features of anaphylaxis",
            "percent": null
        }
    ]
}